Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2026American Journal of Hematology

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJulio C. ChávezMBMariana Bastos‐OreiroCDCatherine Diefenbach

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates efficacy of Mosun-Pola versus R-Pola in relapsed large B-cell lymphoma, indicating a significant therapeutic advantage.

Key Points

  • The study aims to compare the efficacy of subcutaneous mosunetuzumab plus polatuzumab vedotin versus rituximab plus polatuzumab vedotin in patients with relapsed or refractory large B-cell lymphoma.
  • Phase II randomized trial with patients having relapsed/refractory LBCL and ≥ 1 prior therapy.
  • Patients received either Mosun-Pola or R-Pola with specified dosing schedules.
  • Primary endpoint was best objective response rate.
  • Best objective response rate was 77.5% for Mosun-Pola versus 50.0% for R-Pola (p<0.001).
  • Median progression-free survival was significantly longer at 25.4 months for Mosun-Pola compared to 6.4 months for R-Pola (HR 0.47).
  • Cytokine release syndrome occurred in 12.5% of Mosun-Pola patients, all Grade 1/2.

Cite This Study

Chávez et al. (2026) studied this question.

synapsesocial.com/papers/6a2e482cb1cc60ccdea8c767https://doi.org/10.1002/ajh.70403
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial2025 · 22 citations
  2. 2Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial2026
  3. 3Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).2024 · 2 citations
  4. 4Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study2025 · 1 citations
  5. 5Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma2025